Expiration date: 11/2025

The composition and form of issue:

1 tablet coated liner contains losartan potassium 50 mg and hydrochlorothiazide 12.5 mg in blister packs 14 PCs., in box 1 blister.

Pharmacological action:

Blocks the angiotensin II receptor (subtype AT1).

Description pharmacological action:

The maximum hypotensive effect is achieved within 3 weeks after the start of treatment. Efficiency does not depend on age and gender.

Clinical pharmacology:

Reduces the loss of potassium and hyperuricemia, observed with the isolated use of hydrochlorothiazide does not require dose adjustment for the elderly and patients with renal insufficiency (except severe cases) is preferred for patients in whom combination therapy is recommended.

Indications:

Hypertension.

Contraindications:

Hypersensitivity (including to a derivative of sulfanilamide), anuria, childhood.

Application of pregnancy and breast-feeding:

Contraindicated in pregnancy, especially in II and III trimesters of pregnancy due to possible risk of developmental defects or fetal death. In the appointment during lactation should take into account the possibility of penetration into the breast milk. In this regard, if necessary, cancel the drug or stop breast-feeding.

Side effects:

Dizziness, rarely, angioneurotic edema (person, lips, language), hyperkalemia.

Drug interactions:

Compatible (additive effect) etc. antihypertensive drugs. The likelihood of orthostatic hypotension and increase alcohol, barbiturates, narcotic analgesics, the loss of electrolytes, hypokalemia corticosteroids and ACTH increases the antidepoliarizuth miorelaksantov, lithium toxicity weakens — agonists cholestyramine and colestipol reduce absorption in the gastrointestinal tract, and NSAIDs may reduce diuretic, natriuretic and hypotensive effects.

Method of application and dose:

Inside, regardless of meals on the table 1-2. 1 time per day.

Overdose:

The most likely symptoms associated with losartan: hypotension and tachycardia (possible vagal bradycardia) and hydrochlorothiazide: hypokalemia, gipohloremia, hyponatremia, dehydration (due to the enhanced diuresis). Symptomatic treatment includes correction of dehydration, electrolyte imbalance, hypotension and liver function, with the prior elimination of the drug and a gastric lavage (if the drug passed recently). Note that losartan and its metabolites not removed by hemodialysis (dialysis efficiency in relation to thiazide not installed).

Precautions:

It is not recommended to appoint patients with hepatic and severe renal (Cl creatinine less than or equal to 30 ml/min) insufficiency. During treatment should regularly monitor the performance of water-electrolyte balance, glucose, cholesterol and triglycerides in the blood plasma. You may need dose adjustment in combined administration with antidiabetic drugs.